Search PubMed⌕ Search

Biomedical subjects

M Hanada

Publications and source records attributed to M Hanada.

At least 127 records · Page 7Linked to original sources
PubMed1989

[Lymphoblastic lymphoma associated with subcutaneous nodules, intramuscular mass, pericardial effusion and peripheral lymphadenopathy].

A 14-year-old boy was admitted to Department of Pediatrics at Mie University Hospital with a 12-day history of facial cervical edema associated with venous dilatation on the upper chest wall. On admission anterior mediastinal mass was found on chest X-ray film and computed tomography. A needle biopsy revealed non-Hodgkin's lymphoma, diffuse lymphoblastic type and he was staged as III. He was treated with High-risk lymphoma protocol and achieved complete remission. At relapse he developed various manifestations unusual for lymphoblastic lymphoma including peripheral lymphadenopathy, an intramuscular mass of the lt-lower leg, multiple subcutaneous nodules at anterior chest wall and upper abdomen, and pericardial effusion. No lymphomatous infiltration into bone marrow or central nervous system was observed throughout his clinical course. Immunological phenotype of lymphoma cells from pericardial effusion was quite compatible with that of common thymocytes. However cytogenetic analysis showed unique translocation: (2; 5) (q 33; q 35). Translocations with a break at 5 q 35 have been reported in peripheral T-cell lymphoma and malignant histiocytosis.

Adolescent↗
PubMed1989

[Effects of acetylcholine and carbachol on the iris sphincter].

We compared the effects of acetylcholine and carbachol on iris sphincters. The muscle strips (mostly bovine tissues) were isolated and incubated in a 0.2ml organ bath. Results revealed an approximately ten-thousandfold difference in potency between carbachol and acetylcholine, in the bovine iris. Acetylcholine and/or endogenous chemical agents were spontaneously released from bovine tissue. Acetylcholinesterase activity in this tissue strongly inhibited the acetylcholine action, in order to protect the nerve terminals from random depolarization due to the released acetylcholine. Among several species (bovine, rabbit, hamster), Ach action was the least in the bovine iris sphincter muscle.

Acetylcholine↗
PubMed1989

[Responses between iris sphincter and dilator evoked by cholinergic nerve stimulation].

Responses of bovine iris sphincter and dilator evoked by electrical stimulation were recorded in vitro. In order to examine the time course of the iris sphincter and the dilator, the two muscle strips were investigated under the same conditions; i.e., the iris sphincter and the dilator were immersed in parallel in a 0.5 ml organ bath, thus perfused with the same fluid and stimulated by the same electrical pulses. Remarkable difference was found in the time courses between the iris sphincter and the dilator, and this difference was discussed in relation to pupil movement.

Animals↗
PubMed1988

Granulocytic sarcoma of testis preceding acute myelocytic leukemia.

A unique case of granulocytic sarcoma of the testis as a first manifestation of acute myelocytic leukemia preceding hematologic pathology is reported. The testicular specimen was identified by immunoperoxidase staining to be composed of immature granulocytes. Acute myelocytic leukemia of which the first manifestation is a primary testicular tumor is extremely rare, and the related literature is reviewed.

Aged↗
PubMed1988

[A case of fibrous pseudotumor of the spermatic cord].

A case of fibrous pseudotumor of the left spermatic cord is reported. The patient was a 4-year-old boy with the complaint of swelling and pain of the left scrotal contents. An intrascrotal tumor was suspected and surgical exploration was carried out. A small tumor was resected and histological examination revealed fibrous pseudotumor. This tumor was not a true neoplasm, but was due to an inflammatory disease. The clinical and histological findings of the tumor are discussed.

Child, Preschool↗
PubMed1987

Potential limitation of growth-inhibitory action of recombinant human tumor necrosis factor (PAC-4D) due to easy induction of resistance: evidence in vitro.

The growth-inhibitory activity of recombinant human tumor necrosis factor (rH-TNF: PAC-4D) against 32 human cultured cell lines derived from leukemias and lymphomas (7 T cell, 11 B cell, 5 non-T,non-B cell and 9 myeloid cell lines) was measured quantitatively by in vitro regrowth assay. The growth of two non-T,non-B-cell lines (Reh, P30/OHK) and six myeloid cell lines (ML-1, U937, THP-1-0, P31/FUJ, P39/TSU, HEL) was found to be significantly inhibited by a 72 hr treatment with PAC-4D. Although the levels of sensitivity of these cell lines to PAC-4D were different, it was common to all these cell lines that increasing the dose of PAC-4D did not augment the growth-inhibitory action above a certain level. Neither dose-dependent nor time-dependent growth-inhibitory action was observed, namely, exposure to 100 U/ml of PAC-4D for 48 hr was sufficient to exhibit maximum growth-inhibitory action. Furthermore U937 cells were found to become completely resistant to PAC-4D during a continuous 12-day exposure to it. This resistance, however, was lost on culture of the cells with PAC-4D-free growth medium for 15 days. These results suggested that some non-T,non-B acute lymphoblastic leukemias and acute myelogenous leukemias might show an initial response to PAC-4D therapy, but prolonged administration might induce resistance to PAC-4D rather than increase the anti-tumor effect.

Drug Resistance↗
PubMed1987

[Autologous bone marrow transplantation in osteosarcoma].

Four patients with osteosarcoma were treated with intensive chemotherapy and autologous bone marrow transplantation (ABMT). The patients received high-dose methotrexate (9-12 mg/m2) with citrovorum factor rescue, high-dose melphalan (60 mg/m2 X 3), actinomycin D (0.5 mg/m2 X 3), adriamycin (30 mg/m2 X 2) and high-dose cyclophosphamide (60 mg/kg X 2) during 4 weeks. Bone marrow was aspirated and cryopreserved before treatment and reinfused 48 hours after the completion of chemotherapy. Two of four patients had advanced osteosarcoma with multiple pulmonary metastasis, one of whom had responded well and achieved partial response while the other had shown no response, and both patients died of disease progression 4 and 11 months after ABMT, respectively. The other two patients who received this regimen at an earlier disease stage for prevention of pulmonary metastasis, are alive and well without any evidence of metastasis 31 and 18 months after ABMT, respectively. This regimen was tolerated well in all patients except for mild nausea and vomiting. No infectious episodes were observed during the period of aplasia which continued for 19 to 38 days after marrow infusion. These results suggest that this supralethal combination chemotherapy is safe and tolerable when used with ABMT and effective for patients with osteosarcoma, especially when applied in the non-metastatic phase.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1987

[Synchronous triple primary malignant neoplasms in a 42-year-old female].

Synchronous triple primary malignant neoplasms, namely, retroperitoneal myxoid liposarcoma, sigmoid colon carcinoma and uterocervical carcinoma in situ in a 42-year-old female is reported. The retroperitoneal sarcoma and colonic carcinoma were resected simultaneously, while a hysterectomy was performed five months later. No genetic influence could be elicited in the present case. The synchronous triple primary, malignant neoplasms in this case should be considered as having arisen by mere chance. Other cases in which triple or more primary malignancies were resected are briefly reviewed. In addition, cases of triple or more primary malignant tumors with include at least one sarcoma are also reviewed.

Adenocarcinoma↗